514 related articles for article (PubMed ID: 27426936)
1. Short-versus long-term Dual Antiplatelet therapy after drug-eluting stent implantation in women versus men: A sex-specific patient-level pooled-analysis of six randomized trials.
Sawaya FJ; Morice MC; Spaziano M; Mehran R; Didier R; Roy A; Valgimigli M; Kim HS; Woo Park K; Hong MK; Kim BK; Jang Y; Feres F; Abizaid A; Costa RA; Colombo A; Chieffo A; Giustino G; Stone GW; Bhatt DL; Palmerini T; Gilard M
Catheter Cardiovasc Interv; 2017 Feb; 89(2):178-189. PubMed ID: 27426936
[TBL] [Abstract][Full Text] [Related]
2. Short- versus long-term dual antiplatelet therapy after drug-eluting stent implantation: an individual patient data pairwise and network meta-analysis.
Palmerini T; Sangiorgi D; Valgimigli M; Biondi-Zoccai G; Feres F; Abizaid A; Costa RA; Hong MK; Kim BK; Jang Y; Kim HS; Park KW; Mariani A; Della Riva D; Genereux P; Leon MB; Bhatt DL; Bendetto U; Rapezzi C; Stone GW
J Am Coll Cardiol; 2015 Mar; 65(11):1092-102. PubMed ID: 25790880
[TBL] [Abstract][Full Text] [Related]
3. Shorter (≤6 months) versus longer (≥12 months) duration dual antiplatelet therapy after drug eluting stents: a meta-analysis of randomized clinical trials.
Pandit A; Giri S; Hakim FA; Fortuin FD
Catheter Cardiovasc Interv; 2015 Jan; 85(1):34-40. PubMed ID: 24753084
[TBL] [Abstract][Full Text] [Related]
4. 6- Versus 24-Month Dual Antiplatelet Therapy After Implantation of Drug-Eluting Stents in Patients Nonresistant to Aspirin: Final Results of the ITALIC Trial (Is There a Life for DES After Discontinuation of Clopidogrel).
Didier R; Morice MC; Barragan P; Noryani AAL; Noor HA; Majwal T; Hovasse T; Castellant P; Schneeberger M; Maillard L; Bressolette E; Wojcik J; Delarche N; Blanchard D; Jouve B; Ormezzano O; Paganelli F; Levy G; Sainsous J; Carrie D; Furber A; Berlan J; Darremont O; Le Breton H; Lyuycx-Bore A; Gommeaux A; Cassat C; Kermarrec A; Cazaux P; Druelles P; Dauphin R; Armengaud J; Dupouy P; Champagnac D; Ohlmann P; Ben Amer H; Kiss RG; Ungi I; Gilard M
JACC Cardiovasc Interv; 2017 Jun; 10(12):1202-1210. PubMed ID: 28641840
[TBL] [Abstract][Full Text] [Related]
5. Short-Term Versus Long-Term Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation in Elderly Patients: A Meta-Analysis of Individual Participant Data From 6 Randomized Trials.
Lee SY; Hong MK; Palmerini T; Kim HS; Valgimigli M; Feres F; Colombo A; Gilard M; Shin DH; Kim JS; Kim BK; Ko YG; Choi D; Jang Y; Stone GW
JACC Cardiovasc Interv; 2018 Mar; 11(5):435-443. PubMed ID: 29454730
[TBL] [Abstract][Full Text] [Related]
6. Risk of Early Adverse Events After Clopidogrel Discontinuation in Patients Undergoing Short-Term Dual Antiplatelet Therapy: An Individual Participant Data Analysis.
Piccolo R; Feres F; Abizaid A; Gilard M; Morice MC; Hong MK; Kim HS; Colombo A; Bhatt DL; Palmerini T; Stone GW; Windecker S; Valgimigli M
JACC Cardiovasc Interv; 2017 Aug; 10(16):1621-1630. PubMed ID: 28838471
[TBL] [Abstract][Full Text] [Related]
7. Prognostic implications of early and long-term bleeding events in patients on one-year dual antiplatelet therapy following drug-eluting stent implantation.
Musumeci G; Rossini R; Lettieri C; Capodanno D; Romano M; Rosiello R; Guagliumi G; Valsecchi O; Gavazzi A; Angiolillo DJ
Catheter Cardiovasc Interv; 2012 Sep; 80(3):395-405. PubMed ID: 22109961
[TBL] [Abstract][Full Text] [Related]
8. Sex Differences in the Clinical Impact of High Platelet Reactivity After Percutaneous Coronary Intervention With Drug-Eluting Stents: Results From the ADAPT-DES Study (Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents).
Yu J; Mehran R; Baber U; Ooi SY; Witzenbichler B; Weisz G; Rinaldi MJ; Neumann FJ; Metzger DC; Henry TD; Cox DA; Duffy PL; Mazzaferri EL; Brodie BR; Stuckey TD; Maehara A; Xu K; Ben-Yehuda O; Kirtane AJ; Stone GW
Circ Cardiovasc Interv; 2017 Feb; 10(2):. PubMed ID: 28193677
[TBL] [Abstract][Full Text] [Related]
9. Impact of proton pump inhibitors and dual antiplatelet therapy cessation on outcomes following percutaneous coronary intervention: Results From the PARIS Registry.
Chandrasekhar J; Bansilal S; Baber U; Sartori S; Aquino M; Farhan S; Vogel B; Faggioni M; Giustino G; Ariti C; Colombo A; Chieffo A; Kini A; Saporito R; Michael Gibson C; Witzenbichler B; Cohen D; Moliterno D; Stuckey T; Henry T; Pocock S; Dangas G; Gabriel Steg P; Mehran R
Catheter Cardiovasc Interv; 2017 Jun; 89(7):E217-E225. PubMed ID: 27650638
[TBL] [Abstract][Full Text] [Related]
10. Safety of an abbreviated duration of dual antiplatelet therapy (≤6 months) following second-generation drug-eluting stents for coronary artery disease: A systematic review and meta-analysis of randomized trials.
Ziada KM; Abdel-Latif AK; Charnigo R; Moliterno DJ
Catheter Cardiovasc Interv; 2016 Mar; 87(4):722-732. PubMed ID: 26309050
[TBL] [Abstract][Full Text] [Related]
11. Dual Antiplatelet Therapy for 6 Versus 18 Months After Biodegradable Polymer Drug-Eluting Stent Implantation.
Nakamura M; Iijima R; Ako J; Shinke T; Okada H; Ito Y; Ando K; Anzai H; Tanaka H; Ueda Y; Takiuchi S; Nishida Y; Ohira H; Kawaguchi K; Kadotani M; Niinuma H; Omiya K; Morita T; Zen K; Yasaka Y; Inoue K; Ishiwata S; Ochiai M; Hamasaki T; Yokoi H;
JACC Cardiovasc Interv; 2017 Jun; 10(12):1189-1198. PubMed ID: 28641838
[TBL] [Abstract][Full Text] [Related]
12. Long-term outcomes in patients with acute coronary syndromes related to prolonging dual antiplatelet therapy more than 12 months after coronary stenting.
Wimmer NJ; Dufour AB; Cho K; Gagnon DR; Quach L; Ly S; Do JM; Ostrowski S; Michael Gaziano J; Faxon DP; Kinlay S
Catheter Cardiovasc Interv; 2017 Jun; 89(7):1176-1184. PubMed ID: 27860195
[TBL] [Abstract][Full Text] [Related]
13. Optimal Duration of Dual Antiplatelet Therapy After DES Implantation: A Meta-Analysis of 11 Randomized Trials.
Verdoia M; Schaffer A; Barbieri L; Montalescot G; Collet JP; Colombo A; Suryapranata H; De Luca G
Angiology; 2016 Mar; 67(3):224-38. PubMed ID: 26069031
[TBL] [Abstract][Full Text] [Related]
14. Risk-Benefit Profile of Longer-Than-1-Year Dual-Antiplatelet Therapy Duration After Drug-Eluting Stent Implantation in Relation to Clinical Presentation.
Palmerini T; Bruno AG; Gilard M; Morice MC; Valgimigli M; Montalescot G; Collet JP; Della Riva D; Bacchi-Reggiani ML; Steg PG; Diallo A; Vicaut E; Helft G; Nakamura M; Généreux P; Vahl TP; Stone GW
Circ Cardiovasc Interv; 2019 Mar; 12(3):e007541. PubMed ID: 30871353
[TBL] [Abstract][Full Text] [Related]
15. Benefits of short-term or prolonged as compared to standard 1 year DAPT in patients with acute coronary syndrome treated with drug-eluting stents: a meta-analysis of 9 randomized trials.
Verdoia M; Kedhi E; Suryapranata H; Frati G; Biondi-Zoccai G; De Luca G
J Thromb Thrombolysis; 2020 Aug; 50(2):337-354. PubMed ID: 31919736
[TBL] [Abstract][Full Text] [Related]
16. Two-year outcomes after first- or second-generation drug-eluting or bare-metal stent implantation in all-comer patients undergoing percutaneous coronary intervention: a pre-specified analysis from the PRODIGY study (PROlonging Dual Antiplatelet Treatment After Grading stent-induced Intimal hyperplasia studY).
Valgimigli M; Tebaldi M; Borghesi M; Vranckx P; Campo G; Tumscitz C; Cangiano E; Minarelli M; Scalone A; Cavazza C; Marchesini J; Parrinello G;
JACC Cardiovasc Interv; 2014 Jan; 7(1):20-8. PubMed ID: 24332420
[TBL] [Abstract][Full Text] [Related]
17. Benefits and Risks of Extended Dual Antiplatelet Therapy After Everolimus-Eluting Stents.
Hermiller JB; Krucoff MW; Kereiakes DJ; Windecker S; Steg PG; Yeh RW; Cohen DJ; Cutlip DE; Massaro JM; Hsieh WH; Mauri L;
JACC Cardiovasc Interv; 2016 Jan; 9(2):138-47. PubMed ID: 26793956
[TBL] [Abstract][Full Text] [Related]
18. Short term versus long term dual antiplatelet therapy after implantation of drug eluting stent in patients with or without diabetes: systematic review and meta-analysis of individual participant data from randomised trials.
Gargiulo G; Windecker S; da Costa BR; Feres F; Hong MK; Gilard M; Kim HS; Colombo A; Bhatt DL; Kim BK; Morice MC; Park KW; Chieffo A; Palmerini T; Stone GW; Valgimigli M
BMJ; 2016 Nov; 355():i5483. PubMed ID: 27811064
[TBL] [Abstract][Full Text] [Related]
19. Reduced antiplatelet therapy after drug-eluting stenting: multicenter Janus Flex carbostent implantation with short dual antiplatelet treatment for 2 or 6 months-MATRIX study.
Cassese S; De Luca G; Villari B; Berti S; Bellone P; Alfieri A; Montinaro A; Quaranta G; Marraccini P; Piscione F;
Catheter Cardiovasc Interv; 2012 Sep; 80(3):408-16. PubMed ID: 21735531
[TBL] [Abstract][Full Text] [Related]
20. Meta-analysis of everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease: final 3-year results of the SPIRIT clinical trials program (Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions).
Dangas GD; Serruys PW; Kereiakes DJ; Hermiller J; Rizvi A; Newman W; Sudhir K; Smith RS; Cao S; Theodoropoulos K; Cutlip DE; Lansky AJ; Stone GW
JACC Cardiovasc Interv; 2013 Sep; 6(9):914-22. PubMed ID: 24050859
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
